Cardiology

A retrospective analysis of patients with suspected myocarditis following COVID-19 vaccination provides clinicians with insight into the disease course, treatment, and imaging findings among this patient population.

A report published in Circulation details per month increases in both systolic and diastolic blood pressure observed during the pandemic as compared with prepandemic periods.

A case for more proactive lipid-lowering treatment initiation in a high-risk population.

Lipid testing rates are very low among those under 40 years old. Where do clinicians best target high-risk patients—and how?

A 31-person task force has composed and released new multispecialty recommendations for management and diagnosis of diabetes and cardiometabolic disease.

A 31-person task force has composed and released new multispecialty recommendations for management and diagnosis of diabetes and cardiometabolic disease.

Data show the relative expression of SORT1 gene was upregulated by 4.438 fold in patients with CAD, compared to control.

Data show all 7 studies using relative risk found an association between metabolic syndrome and the development of PAD, but one study (RR: 1.31).

The DCRM Task Force recommendations were described as first-of-its-kind guidance for patients with overlapping diabetic, cardiorenal and metabolic disease.

Data show cfPWV at 17.7 years was independently and directly associated with total fat mass and trunk fat mass at 24.5 years.

Investigators also reported that cardiorespiratory fitness was superior in patients with complete revascularization when compared to the patients with incomplete revascularization.

Dr. Paul Thompson offers perspective on the recent "Pollution and the Heart" article published in NEJM and provides insight into the potential for metal pollution from beer on influencing risk of cardiovascular disease.

Adults 40 years and younger generally aren't tested for lipid level risk—a byproduct of national guidance and clinical trial needs.

Data show the absolute risk difference for the development of PPHN after exposure to antidepressants in late pregnancy was 1.3 per 1000 infants.

Recurrent VTE shows a higher rate than expected for patients with subsegmental pulmonary embolism without proximal deep vein thrombosis managed without anticoagulation.

Dr. Gregory Weiss reviews a recent BMJ article detailing sodium content in processed meats and fish in different countries throughout the world and the implications it could have on cardiovascular health at a national level.

Data show the multivariable-adjusted HR for increase in seafood consumption of 1 oz per day and all-cause mortality was 0.84 and for CVD-related mortality was 0.89.

Our latest cardiology case report from Dr. Brady Pregerson features a woman in her mid-20s presenting to the emergency department with chest pain for the last 24 hours and a slight cough.

November's cardiology month in review features stories from the AHA's late-breaking sessions and Kidney Week 2021.

Patients considered adherent to caFFR had a significantly lower risk of MACE, compared to non-adherent patients (adjusted hazard ratio, 0.33).

Dr. Gregory Weiss offers a breakdown of the recent ESC guidelines for management of cardiovascular disease during the ongoing COVID-19 pandemic, including specific insight into care pathways, treatment, and follow-up.

There was no differences in complications by site in either the left or right subclavian vein.

Undergoing bariatric surgery was associated with reductions in risk of adverse liver outcomes and MACE versus nonsurgical management among patients with obesity and biopsy-proven nonalcoholic steatohepatitis in the SPLENDOR study.

Study data show for each $1,000 decrease in median household income, the number of TAVR procedures performed per 100,000 Medicare beneficiaries was 0.2% lower.

An analysis of data from the SPLENDOR study suggests undergoing baraitric surgery was associated with an 88% reduction in risk of progression of fatty liver to cirrhosis, liver cancer, or liver-related death and a 70% reduction in risk of major adverse cardiovascular events in patients with NASH and obesity.